Citi analyst David Lebowitz lowered the firm’s price target on 23andMe to 85c from 90c and keeps a Neutral rating on the shares. 23andMe missed Street expectations in fiscal Q3 on revenue and management noted that the company’s efforts to drive margin expansion through higher kit and subscription prices resulted in lower than anticipated unit volumes for the quarter, the analyst tells investors in a research note. The firm remains cautious on the outlook ahead, saying the full financial impact from ongoing class action claims, as well as persistent headline risk, remains unclear.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ME:
- 23andMe Reports Third Quarter Fiscal 2024 Financial Results
- 23andMe FDA Approval for Novel Cancer Drug Trial
- 23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
- 23andMe announces FDA clearance of IND application for 23ME-01473
- 23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay